Related Experiment Video
Updated: May 2, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Imaging biomarkers for antiangiogenic therapy in malignant gliomas
Abstract:
The discovery that malignant gliomas produce an excessive amount of VEGF, a key mediator of angiogenesis, has heightened interest in developing drugs that block angiogenic pathways. These antiangiogenic drugs tend to decrease vascular permeability, thereby diminishing tumor contrast enhancement independent of anti-tumor effects. This has made the determination of tumor response difficult, since contrast enhancement on post-contrast T1-weighted images is standard for assessing therapy effectiveness. In light of these unique challenges in assessing antiangiogenic therapy, new biomarkers have been proposed, based on advanced magnetic resonance techniques and PET. This article outlines the challenges associated with the evaluation of antiangiogenic therapy in malignant gliomas and describes how new imaging biomarkers can be used to better predict response.
Insights
Malignant gliomas overproduce VEGF, driving tumor growth. Antiangiogenic drugs targeting VEGF face challenges in assessing treatment effectiveness due to reduced tumor enhancement, necessitating new imaging biomarkers for better response prediction.
Area of Science:
- Oncology
- Radiology
- Pharmacology
Background:
- Malignant gliomas overproduce vascular endothelial growth factor (VEGF), a key mediator of angiogenesis.
- Antiangiogenic drugs targeting VEGF pathways are of significant interest for glioma treatment.
- These drugs can reduce tumor vascular permeability, complicating response assessment via standard contrast-enhanced MRI.
Purpose of the Study:
- To outline the challenges in evaluating antiangiogenic therapy for malignant gliomas.
- To describe novel imaging biomarkers for predicting treatment response.
Main Methods:
- Review of current challenges in assessing antiangiogenic therapy efficacy.
- Discussion of advanced magnetic resonance (MR) techniques and positron emission tomography (PET) as sources for new biomarkers.
Main Results:
- Standard contrast enhancement on post-contrast T1-weighted MRI is unreliable for evaluating antiangiogenic therapy due to decreased vascular permeability.
- New imaging biomarkers derived from advanced MR and PET techniques show promise in predicting treatment response.
Conclusions:
- Assessing antiangiogenic therapy response in malignant gliomas requires moving beyond traditional contrast enhancement metrics.
- Advanced imaging biomarkers are crucial for accurately predicting treatment outcomes in patients receiving antiangiogenic agents.
